Literature DB >> 15465611

Interferon-beta induces transient systemic IP-10/CXCL10 chemokine release in patients with multiple sclerosis.

Mathias Buttmann1, Cornelia Merzyn, Peter Rieckmann.   

Abstract

Reduction of chemokine expression induced by human recombinant Interferon (IFN)-beta is thought to be a therapeutic mechanism of its action in the treatment of multiple sclerosis (MS). In vitro, IFN-beta can induce chemokine expression. Here we show that a single injection of IFN-beta induced a transient strong increase of IP-10/CXCL10 and a weak elevation of MCP-1/CCL2 plasma levels in MS patients on continuing treatment with IFN-beta. IP-10/CXCL10 bursts, which were not observed in glatiramer acetate (GA)-treated patients, correlated with occurrence of flu-like symptoms. Systemic IP-10/CXCL10 release induced by IFN-beta may influence its therapeutic effect--either negatively or positively.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15465611     DOI： 10.1016/j.jneuroim.2004.07.016

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN： 0165-5728            Impact factor:   3.478


  18 in total

1.  Adjuvant immunotherapy of experimental autoimmune encephalomyelitis: immature myeloid cells expressing CXCL10 and CXCL16 attract CXCR3+CXCR6+ and myelin-specific T cells to the draining lymph nodes rather than the central nervous system.

Authors:  Richard A O'Connor; Xujian Li; Seth Blumerman; Stephen M Anderton; Randolph J Noelle; Dyana K Dalton
Journal:  J Immunol       Date:  2012-01-27       Impact factor: 5.422

Review 2.  Interfering with interferons in inflammatory bowel disease.

Authors:  S Ghosh; R Chaudhary; M Carpani; R Playford
Journal:  Gut       Date:  2006-08       Impact factor: 23.059

3.  Targeting Enolase in Reducing Secondary Damage in Acute Spinal Cord Injury in Rats.

Authors:  Azizul Haque; Mollie Capone; Denise Matzelle; April Cox; Naren L Banik
Journal:  Neurochem Res       Date:  2017-05-15       Impact factor: 3.996

Review 4.  A comprehensive review on the role of chemokines in the pathogenesis of multiple sclerosis.

Authors:  Soudeh Ghafouri-Fard; Kasra Honarmand; Mohammad Taheri
Journal:  Metab Brain Dis       Date:  2021-01-06       Impact factor: 3.584

5.  Evaluation of serum levels of chemokines during interferon-β treatment in multiple sclerosis patients: a 1-year, observational cohort study.

Authors:  Elizabeth R Comini-Frota; Antonio L Teixeira; Janaína P A Angelo; Marcus V Andrade; Doralina G Brum; Damacio R Kaimen-Maciel; Norma T Foss; Eduardo A Donadi
Journal:  CNS Drugs       Date:  2011-11-01       Impact factor: 5.749

Review 6.  Interferon-β exacerbates Th17-mediated inflammatory disease.

Authors:  Robert C Axtell; Chander Raman; Lawrence Steinman
Journal:  Trends Immunol       Date:  2011-04-29       Impact factor: 16.687

7.  Novel approaches to detect serum biomarkers for clinical response to interferon-beta treatment in multiple sclerosis.

Authors:  Kaushal S Gandhi; Fiona C McKay; Eve Diefenbach; Ben Crossett; Stephen D Schibeci; Robert N Heard; Graeme J Stewart; David R Booth; Jonathan W Arthur
Journal:  PLoS One       Date:  2010-05-05       Impact factor: 3.240

Review 8.  Predictors of Response to Multiple Sclerosis Therapeutics in Individual Patients.

Authors:  Harald Hegen; Michael Auer; Florian Deisenhammer
Journal:  Drugs       Date:  2016-10       Impact factor: 9.546

9.  Interferon-beta therapy in multiple sclerosis: the short-term and long-term effects on the patients' individual gene expression in peripheral blood.

Authors:  Michael Hecker; Christiane Hartmann; Ole Kandulski; Brigitte Katrin Paap; Dirk Koczan; Hans-Juergen Thiesen; Uwe Klaus Zettl
Journal:  Mol Neurobiol       Date:  2013-05-01       Impact factor: 5.590

10.  Vitamin D supplementation for patients with multiple sclerosis treated with interferon-beta: a randomized controlled trial assessing the effect on flu-like symptoms and immunomodulatory properties.

Authors:  Daniel Golan; Basheer Halhal; Lea Glass-Marmor; Elsebeth Staun-Ram; Orit Rozenberg; Idit Lavi; Sara Dishon; Mira Barak; Sophia Ish-Shalom; Ariel Miller
Journal:  BMC Neurol       Date:  2013-06-14       Impact factor: 2.474
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.